Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Early Detection of Peripheral Blood Cell Signature in Children Developing Beta-Cell Autoimmunity at a Young Age.

Kallionpää H, Somani J, Tuomela S, Ullah U, de Albuquerque R, Lönnberg T, Komsi E, Siljander H, Honkanen J, Härkönen T, Peet A, Tillmann V, Chandra V, Anagandula MK, Frisk G, Otonkoski T, Rasool O, Lund R, Lähdesmäki H, Knip M, Lahesmaa R.

Diabetes. 2019 Jul 16. pii: db190287. doi: 10.2337/db19-0287. [Epub ahead of print]

PMID:
31311800
2.

Genome editing of human pancreatic beta cell models: problems, possibilities and outlook.

Balboa D, Prasad RB, Groop L, Otonkoski T.

Diabetologia. 2019 Aug;62(8):1329-1336. doi: 10.1007/s00125-019-4908-z. Epub 2019 Jun 3. Review.

3.

Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.

Haikala HM, Anttila JM, Marques E, Raatikainen T, Ilander M, Hakanen H, Ala-Hongisto H, Savelius M, Balboa D, Von Eyss B, Eskelinen V, Munne P, Nieminen AI, Otonkoski T, Schüler J, Laajala TD, Aittokallio T, Sihto H, Mattson J, Heikkilä P, Leidenius M, Joensuu H, Mustjoki S, Kovanen P, Eilers M, Leverson JD, Klefström J.

Nat Commun. 2019 Feb 20;10(1):932. doi: 10.1038/s41467-019-08956-x.

4.

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.

Haikala HM, Anttila JM, Marques E, Raatikainen T, Ilander M, Hakanen H, Ala-Hongisto H, Savelius M, Balboa D, Von Eyss B, Eskelinen V, Munne P, Nieminen AI, Otonkoski T, Schüler J, Laajala TD, Aittokallio T, Sihto H, Mattson J, Heikkilä P, Leidenius M, Joensuu H, Mustjoki S, Kovanen P, Eilers M, Leverson JD, Klefström J.

Nat Commun. 2019 Feb 6;10(1):620. doi: 10.1038/s41467-019-08541-2. Erratum in: Nat Commun. 2019 Feb 20;10(1):932.

5.

Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes.

Balboa D, Saarimäki-Vire J, Borshagovski D, Survila M, Lindholm P, Galli E, Eurola S, Ustinov J, Grym H, Huopio H, Partanen J, Wartiovaara K, Otonkoski T.

Elife. 2018 Nov 9;7. pii: e38519. doi: 10.7554/eLife.38519.

6.

MANF Is Required for the Postnatal Expansion and Maintenance of Pancreatic β-Cell Mass in Mice.

Danilova T, Belevich I, Li H, Palm E, Jokitalo E, Otonkoski T, Lindahl M.

Diabetes. 2019 Jan;68(1):66-80. doi: 10.2337/db17-1149. Epub 2018 Oct 10.

7.

Concise Review: Human Pluripotent Stem Cells for the Modeling of Pancreatic β-Cell Pathology.

Balboa D, Saarimäki-Vire J, Otonkoski T.

Stem Cells. 2019 Jan;37(1):33-41. doi: 10.1002/stem.2913. Epub 2018 Dec 2. Review.

PMID:
30270471
8.

Pancreatic β-cell tRNA hypomethylation and fragmentation link TRMT10A deficiency with diabetes.

Cosentino C, Toivonen S, Diaz Villamil E, Atta M, Ravanat JL, Demine S, Schiavo AA, Pachera N, Deglasse JP, Jonas JC, Balboa D, Otonkoski T, Pearson ER, Marchetti P, Eizirik DL, Cnop M, Igoillo-Esteve M.

Nucleic Acids Res. 2018 Nov 2;46(19):10302-10318. doi: 10.1093/nar/gky839.

9.

MANF protects human pancreatic beta cells against stress-induced cell death.

Hakonen E, Chandra V, Fogarty CL, Yu NY, Ustinov J, Katayama S, Galli E, Danilova T, Lindholm P, Vartiainen A, Einarsdottir E, Krjutškov K, Kere J, Saarma M, Lindahl M, Otonkoski T.

Diabetologia. 2018 Oct;61(10):2202-2214. doi: 10.1007/s00125-018-4687-y. Epub 2018 Jul 21.

10.

Human pluripotent reprogramming with CRISPR activators.

Weltner J, Balboa D, Katayama S, Bespalov M, Krjutškov K, Jouhilahti EM, Trokovic R, Kere J, Otonkoski T.

Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.

11.

Generation of a SOX2 reporter human induced pluripotent stem cell line using CRISPR/SaCas9.

Balboa D, Weltner J, Novik Y, Eurola S, Wartiovaara K, Otonkoski T.

Stem Cell Res. 2017 Jul;22:16-19. doi: 10.1016/j.scr.2017.05.005. Epub 2017 May 17.

12.

Generation of an OCT4 reporter human induced pluripotent stem cell line using CRISPR/SpCas9.

Balboa D, Weltner J, Novik Y, Eurola S, Wartiovaara K, Otonkoski T.

Stem Cell Res. 2017 Aug;23:105-108. doi: 10.1016/j.scr.2017.07.006. Epub 2017 Jul 11.

13.

p73 is required for appropriate BMP-induced mesenchymal-to-epithelial transition during somatic cell reprogramming.

Martin-Lopez M, Maeso-Alonso L, Fuertes-Alvarez S, Balboa D, Rodríguez-Cortez V, Weltner J, Diez-Prieto I, Davis A, Wu Y, Otonkoski T, Flores ER, Menéndez P, Marques MM, Marin MC.

Cell Death Dis. 2017 Sep 7;8(9):e3034. doi: 10.1038/cddis.2017.432.

14.

A Strong Contractile Actin Fence and Large Adhesions Direct Human Pluripotent Colony Morphology and Adhesion.

Närvä E, Stubb A, Guzmán C, Blomqvist M, Balboa D, Lerche M, Saari M, Otonkoski T, Ivaska J.

Stem Cell Reports. 2017 Jul 11;9(1):67-76. doi: 10.1016/j.stemcr.2017.05.021. Epub 2017 Jun 15.

15.

An Activating STAT3 Mutation Causes Neonatal Diabetes through Premature Induction of Pancreatic Differentiation.

Saarimäki-Vire J, Balboa D, Russell MA, Saarikettu J, Kinnunen M, Keskitalo S, Malhi A, Valensisi C, Andrus C, Eurola S, Grym H, Ustinov J, Wartiovaara K, Hawkins RD, Silvennoinen O, Varjosalo M, Morgan NG, Otonkoski T.

Cell Rep. 2017 Apr 11;19(2):281-294. doi: 10.1016/j.celrep.2017.03.055.

16.

Regulation of Human Pluripotent Stem Cell-Derived Hepatic Cell Phenotype by Three-Dimensional Hydrogel Models.

Toivonen S, Malinen MM, Küblbeck J, Petsalo A, Urtti A, Honkakoski P, Otonkoski T.

Tissue Eng Part A. 2016 Jul;22(13-14):971-84. doi: 10.1089/ten.TEA.2016.0127. Epub 2016 Jul 7.

PMID:
27329070
17.

Clinical, Genetic, and Biochemical Characteristics of Early-Onset Diabetes in the Finnish Population.

Huopio H, Miettinen PJ, Ilonen J, Nykänen P, Veijola R, Keskinen P, Näntö-Salonen K, Vangipurapu J, Raivo J, Stančáková A, Männistö J, Kuulasmaa T, Knip M, Otonkoski T, Laakso M.

J Clin Endocrinol Metab. 2016 Aug;101(8):3018-26. doi: 10.1210/jc.2015-4296. Epub 2016 May 11.

PMID:
27167055
18.

sept7b is required for the differentiation of pancreatic endocrine progenitors.

Dash SN, Hakonen E, Ustinov J, Otonkoski T, Andersson O, Lehtonen S.

Sci Rep. 2016 Apr 26;6:24992. doi: 10.1038/srep24992.

19.

Executive Summary of IPITA-TTS Opinion Leaders Report on the Future of β-Cell Replacement.

Markmann JF, Bartlett ST, Johnson P, Korsgren O, Hering BJ, Scharp D, Kay TW, Bromberg J, Odorico JS, Weir GC, Bridges N, Kandaswamy R, Stock P, Friend P, Gotoh M, Cooper DK, Park CG, OʼConnell PJ, Stabler C, Matsumoto S, Ludwig B, Choudhary P, Khovatchev B, Rickels MR, Sykes M, Wood K, Kraemer K, Hwa A, Stanley E, Ricordi C, Zimmerman M, Greenstein J, Montanya E, Otonkoski T.

Transplantation. 2016 Jul;100(7):e25-31. doi: 10.1097/TP.0000000000001054. Review.

PMID:
27082827
20.

New tools for experimental diabetes research: Cellular reprogramming and genome editing.

Otonkoski T.

Ups J Med Sci. 2016 May;121(2):146-50. doi: 10.3109/03009734.2016.1149529. Epub 2016 Mar 23. Review.

21.

Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement.

Bartlett ST, Markmann JF, Johnson P, Korsgren O, Hering BJ, Scharp D, Kay TW, Bromberg J, Odorico JS, Weir GC, Bridges N, Kandaswamy R, Stock P, Friend P, Gotoh M, Cooper DK, Park CG, OʼConnell P, Stabler C, Matsumoto S, Ludwig B, Choudhary P, Kovatchev B, Rickels MR, Sykes M, Wood K, Kraemer K, Hwa A, Stanley E, Ricordi C, Zimmerman M, Greenstein J, Montanya E, Otonkoski T.

Transplantation. 2016 Feb;100 Suppl 2:S1-44. doi: 10.1097/TP.0000000000001055. No abstract available.

22.

Genetic Variability Overrides the Impact of Parental Cell Type and Determines iPSC Differentiation Potential.

Kyttälä A, Moraghebi R, Valensisi C, Kettunen J, Andrus C, Pasumarthy KK, Nakanishi M, Nishimura K, Ohtaka M, Weltner J, Van Handel B, Parkkonen O, Sinisalo J, Jalanko A, Hawkins RD, Woods NB, Otonkoski T, Trokovic R.

Stem Cell Reports. 2016 Feb 9;6(2):200-12. doi: 10.1016/j.stemcr.2015.12.009. Epub 2016 Jan 14.

23.

Human pluripotent stem cell based islet models for diabetes research.

Balboa D, Otonkoski T.

Best Pract Res Clin Endocrinol Metab. 2015 Dec;29(6):899-909. doi: 10.1016/j.beem.2015.10.012. Epub 2015 Oct 30. Review.

PMID:
26696518
24.

Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation.

Balboa D, Weltner J, Eurola S, Trokovic R, Wartiovaara K, Otonkoski T.

Stem Cell Reports. 2015 Sep 8;5(3):448-59. doi: 10.1016/j.stemcr.2015.08.001.

25.

Intestinal Commitment and Maturation of Human Pluripotent Stem Cells Is Independent of Exogenous FGF4 and R-spondin1.

Tamminen K, Balboa D, Toivonen S, Pakarinen MP, Wiener Z, Alitalo K, Otonkoski T.

PLoS One. 2015 Jul 31;10(7):e0134551. doi: 10.1371/journal.pone.0134551. eCollection 2015.

26.

Combined negative effect of donor age and time in culture on the reprogramming efficiency into induced pluripotent stem cells.

Trokovic R, Weltner J, Noisa P, Raivio T, Otonkoski T.

Stem Cell Res. 2015 Jul;15(1):254-62. doi: 10.1016/j.scr.2015.06.001. Epub 2015 Jun 11.

27.

Generation of iPSC line HEL47.2 from healthy human adult fibroblasts.

Trokovic R, Weltner J, Otonkoski T.

Stem Cell Res. 2015 Jul;15(1):263-5. doi: 10.1016/j.scr.2015.05.013. Epub 2015 Jun 2.

28.

Generation of iPSC line HEL24.3 from human neonatal foreskin fibroblasts.

Trokovic R, Weltner J, Otonkoski T.

Stem Cell Res. 2015 Jul;15(1):266-8. doi: 10.1016/j.scr.2015.05.012. Epub 2015 Jun 2.

29.

mtDNA Mutagenesis Disrupts Pluripotent Stem Cell Function by Altering Redox Signaling.

Hämäläinen RH, Ahlqvist KJ, Ellonen P, Lepistö M, Logan A, Otonkoski T, Murphy MP, Suomalainen A.

Cell Rep. 2015 Jun 16;11(10):1614-24. doi: 10.1016/j.celrep.2015.05.009. Epub 2015 May 28.

30.

Patient-Specific Induced Pluripotent Stem Cell-Derived RPE Cells: Understanding the Pathogenesis of Retinopathy in Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency.

Polinati PP, Ilmarinen T, Trokovic R, Hyotylainen T, Otonkoski T, Suomalainen A, Skottman H, Tyni T.

Invest Ophthalmol Vis Sci. 2015 May;56(5):3371-82. doi: 10.1167/iovs.14-14007.

PMID:
26024122
31.

Early-onset diabetic E1-DN mice develop albuminuria and glomerular injury typical of diabetic nephropathy.

Hyvönen ME, Dumont V, Tienari J, Lehtonen E, Ustinov J, Havana M, Jalanko H, Otonkoski T, Miettinen PJ, Lehtonen S.

Biomed Res Int. 2015;2015:102969. doi: 10.1155/2015/102969. Epub 2015 Apr 27.

32.

Selective microRNA-Offset RNA expression in human embryonic stem cells.

Asikainen S, Heikkinen L, Juhila J, Holm F, Weltner J, Trokovic R, Mikkola M, Toivonen S, Balboa D, Lampela R, Icay K, Tuuri T, Otonkoski T, Wong G, Hovatta O.

PLoS One. 2015 Mar 30;10(3):e0116668. doi: 10.1371/journal.pone.0116668. eCollection 2015.

33.

Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI).

Andrews PW, Baker D, Benvinisty N, Miranda B, Bruce K, Brüstle O, Choi M, Choi YM, Crook JM, de Sousa PA, Dvorak P, Freund C, Firpo M, Furue MK, Gokhale P, Ha HY, Han E, Haupt S, Healy L, Hei DJ, Hovatta O, Hunt C, Hwang SM, Inamdar MS, Isasi RM, Jaconi M, Jekerle V, Kamthorn P, Kibbey MC, Knezevic I, Knowles BB, Koo SK, Laabi Y, Leopoldo L, Liu P, Lomax GP, Loring JF, Ludwig TE, Montgomery K, Mummery C, Nagy A, Nakamura Y, Nakatsuji N, Oh S, Oh SK, Otonkoski T, Pera M, Peschanski M, Pranke P, Rajala KM, Rao M, Ruttachuk R, Reubinoff B, Ricco L, Rooke H, Sipp D, Stacey GN, Suemori H, Takahashi TA, Takada K, Talib S, Tannenbaum S, Yuan BZ, Zeng F, Zhou Q.

Regen Med. 2015;10(2 Suppl):1-44. doi: 10.2217/rme.14.93. No abstract available.

PMID:
25675265
34.

Integrative genomics and transcriptomics analysis of human embryonic and induced pluripotent stem cells.

Laurila K, Autio R, Kong L, Närvä E, Hussein S, Otonkoski T, Lahesmaa R, Lähdesmäki H.

BioData Min. 2014 Dec 13;7(1):32. doi: 10.1186/s13040-014-0032-2. eCollection 2014.

35.

[Human stem cells in the treatment of pancreatic and hepatic diseases].

Hakonen E, Toivonen S, Jalanko H, Otonkoski T.

Duodecim. 2014;130(19):1973-80. Review. Finnish.

PMID:
25558618
36.

Congenital hyperinsulinism, neonatal diabetes and the risk of malignancies: an international collaborative study. Preliminary communication.

Makov M, Chodick G, Mohnike K, Otonkoski T, Huopio H, Banerjee I, Cave H, Polak M, Christesen HT, Hussain K, Deleon D, Stanley C, Cappa M, Ramos O, Zangen D, Laron Z.

Diabet Med. 2015 May;32(5):701-3. doi: 10.1111/dme.12670. No abstract available.

PMID:
25494966
37.

Advanced feeder-free generation of induced pluripotent stem cells directly from blood cells.

Trokovic R, Weltner J, Nishimura K, Ohtaka M, Nakanishi M, Salomaa V, Jalanko A, Otonkoski T, Kyttälä A.

Stem Cells Transl Med. 2014 Dec;3(12):1402-9. doi: 10.5966/sctm.2014-0113. Epub 2014 Oct 29.

38.

Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3.

Haapaniemi EM, Kaustio M, Rajala HL, van Adrichem AJ, Kainulainen L, Glumoff V, Doffinger R, Kuusanmäki H, Heiskanen-Kosma T, Trotta L, Chiang S, Kulmala P, Eldfors S, Katainen R, Siitonen S, Karjalainen-Lindsberg ML, Kovanen PE, Otonkoski T, Porkka K, Heiskanen K, Hänninen A, Bryceson YT, Uusitalo-Seppälä R, Saarela J, Seppänen M, Mustjoki S, Kere J.

Blood. 2015 Jan 22;125(4):639-48. doi: 10.1182/blood-2014-04-570101. Epub 2014 Oct 27.

39.

Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease.

Flanagan SE, Haapaniemi E, Russell MA, Caswell R, Allen HL, De Franco E, McDonald TJ, Rajala H, Ramelius A, Barton J, Heiskanen K, Heiskanen-Kosma T, Kajosaari M, Murphy NP, Milenkovic T, Seppänen M, Lernmark Å, Mustjoki S, Otonkoski T, Kere J, Morgan NG, Ellard S, Hattersley AT.

Nat Genet. 2014 Aug;46(8):812-814. doi: 10.1038/ng.3040. Epub 2014 Jul 20.

40.

[Induced pluripotent stem cells (iPS) in medical research].

Weltner J, Trokovic R, Otonkoski T.

Duodecim. 2014;130(8):785-92. Review. Finnish.

PMID:
24822328
41.

MANF is indispensable for the proliferation and survival of pancreatic β cells.

Lindahl M, Danilova T, Palm E, Lindholm P, Võikar V, Hakonen E, Ustinov J, Andressoo JO, Harvey BK, Otonkoski T, Rossi J, Saarma M.

Cell Rep. 2014 Apr 24;7(2):366-375. doi: 10.1016/j.celrep.2014.03.023. Epub 2014 Apr 13.

42.

EGFR signaling promotes β-cell proliferation and survivin expression during pregnancy.

Hakonen E, Ustinov J, Palgi J, Miettinen PJ, Otonkoski T.

PLoS One. 2014 Apr 2;9(4):e93651. doi: 10.1371/journal.pone.0093651. eCollection 2014.

43.

Notch signaling regulates the differentiation of neural crest from human pluripotent stem cells.

Noisa P, Lund C, Kanduri K, Lund R, Lähdesmäki H, Lahesmaa R, Lundin K, Chokechuwattanalert H, Otonkoski T, Tuuri T, Raivio T.

J Cell Sci. 2014 May 1;127(Pt 9):2083-94. doi: 10.1242/jcs.145755. Epub 2014 Feb 25.

44.

In vivo activation of the PI3K-Akt pathway in mouse beta cells by the EGFR mutation L858R protects against diabetes.

Hakonen E, Ustinov J, Eizirik DL, Sariola H, Miettinen PJ, Otonkoski T.

Diabetologia. 2014 May;57(5):970-9. doi: 10.1007/s00125-014-3175-2. Epub 2014 Feb 4.

PMID:
24493201
45.

A novel feeder-free culture system for human pluripotent stem cell culture and induced pluripotent stem cell derivation.

Vuoristo S, Toivonen S, Weltner J, Mikkola M, Ustinov J, Trokovic R, Palgi J, Lund R, Tuuri T, Otonkoski T.

PLoS One. 2013 Oct 2;8(10):e76205. doi: 10.1371/journal.pone.0076205. eCollection 2013.

46.

Tissue- and cell-type-specific manifestations of heteroplasmic mtDNA 3243A>G mutation in human induced pluripotent stem cell-derived disease model.

Hämäläinen RH, Manninen T, Koivumäki H, Kislin M, Otonkoski T, Suomalainen A.

Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):E3622-30. doi: 10.1073/pnas.1311660110. Epub 2013 Sep 3.

47.

Activin A and Wnt-dependent specification of human definitive endoderm cells.

Toivonen S, Lundin K, Balboa D, Ustinov J, Tamminen K, Palgi J, Trokovic R, Tuuri T, Otonkoski T.

Exp Cell Res. 2013 Oct 15;319(17):2535-44. doi: 10.1016/j.yexcr.2013.07.007. Epub 2013 Aug 14.

PMID:
23954819
48.

A mouse model of human hyperinsulinism produced by the E1506K mutation in the sulphonylurea receptor SUR1.

Shimomura K, Tusa M, Iberl M, Brereton MF, Kaizik S, Proks P, Lahmann C, Yaluri N, Modi S, Huopio H, Ustinov J, Otonkoski T, Laakso M, Ashcroft FM.

Diabetes. 2013 Nov;62(11):3797-806. doi: 10.2337/db12-1611. Epub 2013 Jul 31.

49.

Comparative analysis of targeted differentiation of human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells reveals variability associated with incomplete transgene silencing in retrovirally derived hiPSC lines.

Toivonen S, Ojala M, Hyysalo A, Ilmarinen T, Rajala K, Pekkanen-Mattila M, Äänismaa R, Lundin K, Palgi J, Weltner J, Trokovic R, Silvennoinen O, Skottman H, Narkilahti S, Aalto-Setälä K, Otonkoski T.

Stem Cells Transl Med. 2013 Feb;2(2):83-93. doi: 10.5966/sctm.2012-0047. Epub 2013 Jan 22.

50.

Lectin from Erythrina cristagalli supports undifferentiated growth and differentiation of human pluripotent stem cells.

Mikkola M, Toivonen S, Tamminen K, Alfthan K, Tuuri T, Satomaa T, Natunen J, Saarinen J, Tiittanen M, Lampinen M, Valmu L, Partanen J, Otonkoski T.

Stem Cells Dev. 2013 Mar 1;22(5):707-16. doi: 10.1089/scd.2012.0365. Epub 2012 Dec 21.

PMID:
23106381

Supplemental Content

Loading ...
Support Center